4D Molecular Therapeutics, Inc.
FDMT
$10.45
$0.111.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 8.81% | 12.90% | -45.79% | -78.49% | -68.75% |
| Total Depreciation and Amortization | 15.46% | 13.72% | 15.46% | 16.35% | 15.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.17% | -9.51% | -1.08% | 2.11% | -3.08% |
| Change in Net Operating Assets | 375.92% | 1,049.35% | -106.12% | 809.19% | -294.50% |
| Cash from Operations | 15.53% | 18.95% | -61.85% | -95.40% | -99.10% |
| Capital Expenditure | 102.56% | 85.84% | 54.08% | -70.09% | -50.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,493.05% | 69.05% | 114.22% | 117.94% | 98.13% |
| Cash from Investing | -674.90% | 69.26% | 113.58% | 116.73% | 96.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 575.67% | -66.51% | -99.54% | -99.42% | -96.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 575.67% | -66.51% | -99.54% | -99.42% | -96.04% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 57.04% | 10.70% | -57.69% | -136.83% | -172.11% |